Revvity Q2 Preview: Can Strong Segments Deliver an Earnings Beat?

Revvity (RVTY) anticipates Q2 2025 revenues of $700M-$715M, reflecting 2-4% organic growth, with adjusted EPS projected at $1.13-$1.15 despite expected gross margin compression to 60% due to tariff impacts. The Diagnostics segment is poised for continued strength, driven by immunodiagnostics, newborn screening advancements, and new product approvals, while the Life Sciences segment's robust Signals Software growth is expected to offset softness in instrumentation. Management is implementing mitigation strategies for tariff headwinds, which are expected to peak in Q2, and the company is predicted by Zacks to deliver an earnings beat.

Analysis

Revvity (RVTY) projects a nuanced financial picture for its second quarter of 2025, balancing solid organic growth against external pressures. The company anticipates 2-4% organic revenue growth, translating to revenues of $700-$715 million, yet the Zacks Consensus Estimate points to a 6.6% year-over-year decline in EPS to $1.14. This expected earnings deterioration is primarily driven by gross margin compression to approximately 60% due to tariff-related headwinds, which management expects to peak in Q2. Segment performance is bifurcated: the Diagnostics division remains a key growth engine, building on its 5% organic growth in Q1 with catalysts like the new FDA-approved T-SPOT automated platform and an expanded Genomics England partnership. In contrast, the Life Sciences segment faces softness in instrumentation from uncertain U.S. academic funding, a headwind impacting over 5% of total company revenue. However, this is reportedly being fully offset by stronger-than-expected growth in the Signals Software business, now projected to grow in the upper teens for the full year. With a history of beating estimates and a positive Earnings ESP of +0.88%, a headline earnings beat is likely, though the underlying margin and segment dynamics warrant close attention.

Key Decisions for Investors

• Investors should scrutinize the segmental results to confirm that the guided upper-teens growth in the Signals Software business is sufficient to fully offset the anticipated weakness in Life Sciences instrumentation.
• Pay close attention to the reported Q2 gross margin relative to the 60% guidance and any management commentary on the effectiveness of tariff mitigation strategies, as this will be a key determinant for profitability in the second half of the year.
• Look beyond the widely anticipated headline earnings beat and focus on the quality of the full-year guidance, particularly concerning the outlook for academic demand and early revenue traction from new products like the IDS i20 platform.